Literature DB >> 11087204

Biological selection of variant-specific surface proteins in Giardia lamblia.

S M Singer1, H G Elmendorf, J T Conrad, T E Nash.   

Abstract

Immune evasion is frequently cited as the main reason for antigenic variation in pathogenic microorganisms. To better understand the role of switching of variant-specific surface proteins (VSPs) in Giardia lamblia-host interactions, antigenic variation during infections of mice and gerbils was examined, using clones that predominantly expressed unique VSPs. As expected, VSPs were selected against during infections of immunocompetent hosts. In contrast, in immunodeficient hosts, some VSPs were selected for and others were selected against. These diverse patterns of selection demonstrate that there are host-VSP interactions that exert both positive and negative selective pressures on parasites, independent of the adaptive immune response. Furthermore, selection was dependent on both the particular VSP and the host. Thus, the large number of VSP genes in G. lamblia may allow the parasite to infect multiple different hosts, and antigenic variation could be a mechanism to expand the parasite's host range.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087204     DOI: 10.1086/317659

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Expression of Anaplasma marginale major surface protein 2 variants in persistently infected ticks.

Authors:  J de la Fuente; K M Kocan
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia.

Authors:  Barbara J Davids; Ching M Liu; Elaine M Hanson; Christine H Y Le; Jonathan Ang; Kurt Hanevik; Marvin Fischer; Matej Radunovic; Nina Langeland; Marcela Ferella; Staffan G Svärd; Majid Ghassemian; Yukiko Miyamoto; Lars Eckmann
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

4.  vsp gene expression by Giardia lamblia clone GS/M-83-H7 during antigenic variation in vivo and in vitro.

Authors:  M Bienz; M Siles-Lucas; P Wittwer; N Müller
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 5.  Behind the smile: cell biology and disease mechanisms of Giardia species.

Authors:  Johan Ankarklev; Jon Jerlström-Hultqvist; Emma Ringqvist; Karin Troell; Staffan G Svärd
Journal:  Nat Rev Microbiol       Date:  2010-04-19       Impact factor: 60.633

6.  Role of interleukin-6 in the control of acute and chronic Giardia lamblia infections in mice.

Authors:  Ping Zhou; Erqiu Li; Nannan Zhu; Jason Robertson; Theodore Nash; Steven M Singer
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

7.  Experimental infections of neonatal mice with cysts of Giardia lamblia clone GS/M-83-H7 are associated with an antigenic reset of the parasite.

Authors:  N von Allmen; M Bienz; A Hemphill; N Müller
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Goblet cells: are they an unspecific barrier against Giardia intestinalis or a gate?

Authors:  Martha Ponce-Macotela; Angélica González-Maciel; Rafael Reynoso-Robles; Mario N Martínez-Gordillo
Journal:  Parasitol Res       Date:  2007-11-25       Impact factor: 2.289

9.  Gene duplication in the genome of parasitic Giardia lamblia.

Authors:  Jun Sun; Huifeng Jiang; Roberto Flores; Jianfan Wen
Journal:  BMC Evol Biol       Date:  2010-02-17       Impact factor: 3.260

Review 10.  A systematic review and meta-analysis of the association between Giardia lamblia and endemic pediatric diarrhea in developing countries.

Authors:  Khitam Muhsen; Myron M Levine
Journal:  Clin Infect Dis       Date:  2012-12       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.